Guiding immunotherapy combinations: Who gets what?
Michelle N Ferreira1, Jennifer H Choe2
1Duke University Medical Center, Durham, NC 27710, United States.
Abstract:
Although PD-1 and CTLA-4 inhibitors have proven successful in a range of malignancies, there are subsets of patients that do not respond to these agents due to upregulation of adaptive and innate resistance mechanisms by the tumor and its surrounding microenvironment. As new immunotherapeutic strategies are developed, there is a need for rational implementation of novel immunotherapy combinations that target complementary mechanisms of immunotherapy resistance intrinsic to each patient and tumor type. In this short review, we cover mechanisms by which tumors evade the immune system, as well as summarize available clinical data on emerging therapeutic agents that target these defense mechanisms. Rational implementation of combination immunotherapy targeting patient- and malignancy-specific immune evasion mechanisms may thus lead to enhanced response rates and allow immunotherapy to be effective even in tumors that are historically considered poorly responsive to immunotherapy.
Insights
New immunotherapies may overcome resistance to PD-1 and CTLA-4 inhibitors by targeting tumor evasion mechanisms. Combination strategies are essential for improving patient response rates in difficult-to-treat cancers.
Area of Science:
- Immunology
- Oncology
- Pharmacology
Background:
- Immune checkpoint inhibitors like PD-1 and CTLA-4 therapies have shown success in treating various cancers.
- However, a significant subset of patients do not respond due to tumor-intrinsic and microenvironment-mediated resistance mechanisms.
Purpose of the Study:
- To review mechanisms of tumor immune evasion and resistance to immunotherapy.
- To summarize clinical data on emerging therapeutic agents targeting these resistance mechanisms.
- To propose rational combination immunotherapy strategies for enhanced efficacy.
Main Methods:
- Literature review of mechanisms of immune evasion.
- Summary of clinical data for novel immunotherapy agents.
- Analysis of combination strategies targeting resistance.
Main Results:
- Tumors employ adaptive and innate resistance mechanisms to evade immune surveillance.
- Emerging agents target specific pathways involved in immunotherapy resistance.
- Combination therapies show promise in preclinical and early clinical studies.
Conclusions:
- Combination immunotherapy targeting patient- and malignancy-specific immune evasion is crucial.
- Novel strategies can enhance response rates and overcome resistance in poorly responsive tumors.
- Personalized immunotherapy approaches are key to maximizing treatment efficacy.
Related Concept Videos
01:27Tumor Immunotherapy
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:40Cell-mediated Immune Responses
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...